• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Janssen Research & Development LLC

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is part of Johnson & Johnson, the world's most broadly based producer of healthcare products. J&JPRD is headquartered in Raritan, New Jersey (USA), and has facilities throughout Europe and the United States. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide. *

 

Please contact us with your proposals. Thank you!

	Start	2012-01-06 renamed before
	Group	Johnson & Johnson (JnJ) (Group)
	Predecessor	Johnson & Johnson Pharmaceutical Research & Development LLC (J&JPRD)
	Industry	drug discovery
	Industry 2	drug development
	Street	920 Rt 202
	City	08869 Raritan, NJ
		Address record changed: 2012-01-06
Basic data	Employees	n. a.
		* Document for �About Section�:
		Record changed: 2019-03-18

Advertisement

More documents for Johnson & Johnson (JnJ) (Group)

• [1] Medicxi Ventures. (7/19/19). "Press Release: Medicxi Closes a New €400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters". London, Geneva & Jersey....
• [2] Genmab A/S. (6/11/19). "Press Release: Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody-CD38". Copenhagen....
• [3] Owlstone Medical Ltd.. (5/20/19). "Press Release: Owlstone Medical Enters into a Strategic Collaboration with Actelion to Develop a Breath-Based Test to Help Facilitate Early Detection of Pulmonary Hypertension". Cambridge....
• [4] MeiraGTx Holdings plc. (5/14/19). "Press Release: MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update". London & New York, NY....
• [5] Iktos. (4/29/19). "Press Release: Iktos Announces Research Collaboration with Janssen to Utilize Iktos’ Artificial Intelligence Technology to Increase Speed & Efficiency of Small Molecule Drug Discovery". Paris....
• [6] MeiraGTx Holdings plc. (3/26/19). "Press Release: MeiraGTx Reports Full Year 2018 Financial Results". London & New York, NY....
• [7] AdoRx Therapeutics Ltd.. (2/28/19). "Press Release: AdoRx Therapeutics Announces Collaboration With Johnson & Johnson Innovation to Develop Novel Lung Cancer Therapeutics". Edinburgh....
• [8] Argenx SE. (2/28/19). "Press Release: Argenx Reports Fourth Quarter Business Update and Full Year 2018 Financial Results". Breda & Ghent....
• [9] MorphoSys AG. (2/27/19). "Press Release: MorphoSys Announces that Its Licensee Janssen Has Received U.S. FDA Approval for Tremfya One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis". Planegg....
• [10] MeiraGTx Holdings plc. (2/27/19). "Press Release: MeiraGTx Announces $80 Million Private Placement of Ordinary Shares". London & New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.